Guidance for market authorization requirements for COVID-19 vaccines: Requirements for vaccines to address SARS-CoV-2 variants

Variant strains of SARS-CoV-2 are emerging that may affect the level of protection provided by currently authorized COVID-19 vaccines. As a result, manufacturers are adapting authorized COVID-19 vaccines to provide protection against infection and disease caused by virus variants.

Data and Resources

Additional Info

Field Value
Last Updated April 17, 2026, 17:23 (UTC)
Created April 17, 2026, 15:34 (UTC)
criticality_level []
geographic_scope []
open_canada_collection publication
open_canada_date_published 2021-03-26 00:00:00
open_canada_keywords {"fr": ["coronavirus", "COVID-19", "pandémie", "médicaments", "médicaments", "vaccins", "autorisation de mise sur le marché", "licence", "importation ou vente", "vaccin COVID-19", "variantes du SRAS-CoV-2"], "en": ["coronavirus", "COVID-19", "pandemic", "drugs", "medications", "vaccines", "market authorization", "licensing", "importing or selling", "COVID-19 vaccine", "SARS-CoV-2 variants"]}
open_canada_subject ["health_and_safety"]
sensitivity_level unrestricted
title_fr Lignes directrices sur les exigences relatives aux autorisations de mise en marché des vaccins contre la COVID-19 : Exigences relatives aux vaccins contre les variants du SRAS-CoV-2
update_frequency as_needed